[시장보고서]세계의 종양 기반 분자진단 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 제품별, 기술별, 지역별, 부문별 예측(2025-2033년)

세계의 종양 기반 분자진단 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 제품별, 기술별, 지역별, 부문별 예측(2025-2033년)

Oncology Based Molecular Diagnostics Market Size, Share & Trends Analysis Report By Type (Breast Cancer, Lung Cancer), By Product (Instruments, Reagents), By Technology (PCR, Sequencing), By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1790381

리서치사 : Grand View Research

발행일 : 2025년 07월

페이지 정보 : 영문 136 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,870,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,361,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,342,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

종양 기반 분자진단 시장 개요

종양 기반 분자진단 세계 시장 규모는 2024년 37억 5,000만 달러로 추정되며, 2025-2033년 연평균 5.5% 성장하여 2030년에는 63억 5,000만 달러에 달할 것으로 예측됩니다. 이 시장은 분자 기술을 통해 유전자 변이, 유전자 발현 패턴, 종양 특이적 바이오마커를 확인하여 다양한 암의 검출, 예후 예측, 모니터링을 지원합니다.

성장의 원동력은 전 세계 암 발병률 증가, 정밀의료 도입 확대, PCR, NGS, 액체생검 플랫폼 등 진단기술의 지속적인 기술 혁신입니다.

또한, 암의 조기 발견과 개인 맞춤형 치료 전략에 대한 수요 증가는 전체 헬스케어 시스템에서 시장 확대에 기여하고 있습니다.

종양 기반 분자진단은 DNA, RNA 또는 단백질을 분석하여 암과 관련된 유전자의 변화를 감지하고 임상적 판단을 유도합니다. 이러한 검사는 다양한 암과 관련된 특정 돌연변이, 유전자 발현, 바이오마커를 확인하여 보다 정확한 진단, 예후, 치료법을 선택할 수 있도록 도와줍니다. 이 검사는 일반적으로 유방암, 폐암, 대장암, 전립선암을 발견하는 데 사용됩니다.

이러한 진단법은 환자를 표적치료에 맞추고 치료 효과를 모니터링함으로써 맞춤형 의료에서 중요한 역할을 합니다. 그 용도는 병원 검사실, 표준 검사실, 연구기관 등 다양합니다. PCR, 차세대 염기서열 분석(NGS), 액체 생검 등의 기술이 지속적으로 발전함에 따라 이러한 검사는 더욱 효율적이고 쉽게 이용할 수 있게 되었습니다. 암 치료가 개인 맞춤형 치료로 전환되는 가운데, 분자진단학은 암 관리의 중요한 요소로 자리 잡고 있습니다.

기업 분류
전략 매핑
- 신형 발매
- 파트너십
- 취득
- 협업
- 자금조달
주요 기업의 시장 점유율 분석(2024년)
기업 히트맵 분석
기업 개요
- Abbott
- Bayer AG
- BD
- Cepheid
- Agilent Technologies, Inc.
- Danaher
- Hologic, Inc.
- Qiagen
- F. Hoffmann-La Roche Ltd.
- Siemens
- Sysmex

LSH

영문 목차

영문목차

Oncology Based Molecular Diagnostics Market Summary

The global oncology based molecular diagnostics market size was estimated at USD 3.75 billion in 2024 and is projected to reach USD 6.35 billion by 2030, growing at a CAGR of 5.5% from 2025 to 2033. This market supports the detection, prognosis, and monitoring of various cancers by identifying genetic mutations, gene expression patterns, and tumor-specific biomarkers through molecular techniques.

Growth is driven by the increasing global cancer burden, growing adoption of precision medicine, and continued innovation in diagnostic technologies such as PCR, NGS, and liquid biopsy platforms.

In addition, rising demand for early cancer detection and personalized therapeutic strategies contributes to market expansion across healthcare systems.

Oncology-based molecular diagnostics involve analyzing DNA, RNA, or proteins to detect cancer-related genetic alterations and guide clinical decisions. These tests help identify specific mutations, gene expressions, or biomarkers associated with various cancers, allowing for more accurate diagnosis, prognosis, and treatment selection. They are commonly used to detect breast, lung, colorectal, and prostate cancers.

These diagnostics play a key role in personalized medicine by helping match patients with targeted therapies and monitoring treatment response. Applications span across hospital labs, reference labs, and research institutions. With continuous improvements in technologies like PCR, next-generation sequencing (NGS), and liquid biopsy, these tests are becoming more efficient and accessible. With oncology care shifting toward individualized treatment, molecular diagnostics have become a critical component of cancer management.

Global Oncology Based Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oncology based molecular diagnostics market report based on product, technology, type, and region:

Type Outlook (Revenue, USD Million; 2021 - 2033)
Breast Cancer
Prostate Cancer
Colorectal Cancer
Cervical Cancer
Liver Cancer
Lung Cancer
Blood Cancer
Kidney Cancer
Others
Product Outlook (Revenue, USD Million; 2021 - 2033)
Instruments
Reagents
Others
Technology Outlook (Revenue, USD Million; 2021 - 2033)
PCR
In situ hybridization
INAAT
Chips and microarrays
Mass spectrometry
Sequencing
TMA
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Oncology Based Molecular Diagnostics Market: Methodology and Scope

1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
  - 1.1.1.1. Type Segment
  - 1.1.1.2. Product Segment
  - 1.1.1.3. Technology segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
- 1.4.1. Objective - 1
- 1.4.2. Objective - 2
- 1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
1.7. Information or Data Analysis
- 1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
- 1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations

Chapter 2. Oncology Based Molecular Diagnostics Market: Executive Summary

2.1. Market Snapshot
2.2. Type and Product Snapshot
2.3. Technology Snapshot
2.4. Competitive Landscape Snapshot

Chapter 3. Oncology Based Molecular Diagnostics Market Variables, Trends, & Scope

3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
- 3.4.1. Rising Global Cancer Prevalence
- 3.4.2. Adoption of Precision Medicine
- 3.4.3. Advances in Molecular Testing Technologies
3.5. Market Restraint Analysis
- 3.5.1. High Costs of Testing and Equipment
- 3.5.2. Inconsistent Reimbursement and Regulatory Frameworks
- 3.5.3. Limited Access in Low-Resource Regions
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis
3.8. Pipeline Analysis

Chapter 4. Oncology Based Molecular Diagnostics Market: Type Estimates & Trend Analysis

4.1. Oncology Based Molecular Diagnostics Market: Type Movement Analysis
4.2. Breast Cancer
- 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3. Prostate Cancer
- 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Colorectal Cancer
- 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Cervical Cancer
- 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Liver Cancer
- 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Lung Cancer
- 4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.8. Blood Cancer
- 4.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.9. Kidney Cancer
- 4.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.10. Others
- 4.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Oncology Based Molecular Diagnostics Market: Product Estimates & Trend Analysis

5.1. Oncology Based Molecular Diagnostics Market: Product Movement Analysis
5.2. Instruments
- 5.2.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.3. Reagents
- 5.3.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.4. Others
- 5.4.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Oncology Based Molecular Diagnostics Market: Technology Estimates & Trend Analysis

6.1. Oncology Based Molecular Diagnostics Market: Product Movement Analysis
6.2. PCR
- 6.2.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
6.3. In situ hybridization
- 6.3.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
6.4. INAAT
- 6.4.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
6.5. Chips and microarrays
- 6.5.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
6.6. Mass spectrometry
- 6.6.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
6.7. Sequencing
- 6.7.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
6.8. TMA
- 6.8.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)
6.9. Others
- 6.9.1. Market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Oncology Based Molecular Diagnostics Market: Regional Business Analysis

7.1. Regional Market Snapshot
7.2. North America
- 7.2.1. North America Oncology Based Molecular Diagnostics Market Estimates And Forecast, 2021 - 2033 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.2.2.2. Key Country Dynamics
  - 7.2.2.3. Regulatory Framework
  - 7.2.2.4. Reimbursement Scenario
  - 7.2.2.5. Competitive Scenario
- 7.2.3. Canada
  - 7.2.3.1. Canada Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.2.3.2. Key Country Dynamics
  - 7.2.3.3. Regulatory Framework
  - 7.2.3.4. Reimbursement Scenario
  - 7.2.3.5. Competitive Scenario
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.2.4.2. Key Country Dynamics
  - 7.2.4.3. Regulatory Framework
  - 7.2.4.4. Reimbursement Scenario
  - 7.2.4.5. Competitive Scenario
7.3. Europe
- 7.3.1. Europe Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
- 7.3.2. UK
  - 7.3.2.1. UK Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.3.2.2. Key Country Dynamics
  - 7.3.2.3. Regulatory Framework
  - 7.3.2.4. Reimbursement Scenario
  - 7.3.2.5. Competitive Scenario
- 7.3.3. Germany
  - 7.3.3.1. Germany Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.3.3.2. Key Country Dynamics
  - 7.3.3.3. Regulatory Framework
  - 7.3.3.4. Reimbursement Scenario
  - 7.3.3.5. Competitive Scenario
- 7.3.4. Spain
  - 7.3.4.1. Spain Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.3.4.2. Key Country Dynamics
  - 7.3.4.3. Regulatory Framework
  - 7.3.4.4. Reimbursement Scenario
  - 7.3.4.5. Competitive Scenario
- 7.3.5. France
  - 7.3.5.1. France Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.3.5.2. Key Country Dynamics
  - 7.3.5.3. Regulatory Framework
  - 7.3.5.4. Reimbursement Scenario
  - 7.3.5.5. Competitive Scenario
- 7.3.6. Italy
  - 7.3.6.1. Italy Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.3.6.2. Key Country Dynamics
  - 7.3.6.3. Regulatory Framework
  - 7.3.6.4. Reimbursement Scenario
  - 7.3.6.5. Competitive Scenario
- 7.3.7. Denmark
  - 7.3.7.1. Denmark Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.3.7.2. Key Country Dynamics
  - 7.3.7.3. Regulatory Framework
  - 7.3.7.4. Reimbursement Scenario
  - 7.3.7.5. Competitive Scenario
- 7.3.8. Sweden
  - 7.3.8.1. Sweden Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.3.8.2. Key Country Dynamics
  - 7.3.8.3. Regulatory Framework
  - 7.3.8.4. Reimbursement Scenario
  - 7.3.8.5. Competitive Scenario
- 7.3.9. Norway
  - 7.3.9.1. Norway Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.3.9.2. Key Country Dynamics
  - 7.3.9.3. Regulatory Framework
  - 7.3.9.4. Reimbursement Scenario
  - 7.3.9.5. Competitive Scenario
7.4. Asia Pacific
- 7.4.1. Asia-Pacific Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
- 7.4.2. Japan
  - 7.4.2.1. Japan Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.4.2.2. Key Country Dynamics
  - 7.4.2.3. Regulatory Framework
  - 7.4.2.4. Reimbursement Scenario
  - 7.4.2.5. Competitive Scenario
- 7.4.3. China
  - 7.4.3.1. China Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.4.3.2. Key Country Dynamics
  - 7.4.3.3. Regulatory Framework
  - 7.4.3.4. Reimbursement Scenario
  - 7.4.3.5. Competitive Scenario
- 7.4.4. India
  - 7.4.4.1. India Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.4.4.2. Key Country Dynamics
  - 7.4.4.3. Regulatory Framework
  - 7.4.4.4. Reimbursement Scenario
  - 7.4.4.5. Competitive Scenario
- 7.4.5. South Korea
  - 7.4.5.1. South Korea Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.4.5.2. Key Country Dynamics
  - 7.4.5.3. Regulatory Framework
  - 7.4.5.4. Reimbursement Scenario
  - 7.4.5.5. Competitive Scenario
- 7.4.6. Thailand
  - 7.4.6.1. Thailand Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.4.6.2. Key Country Dynamics
  - 7.4.6.3. Regulatory Framework
  - 7.4.6.4. Reimbursement Scenario
  - 7.4.6.5. Competitive Scenario
- 7.4.7. Australia
  - 7.4.7.1. Australia Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.4.7.2. Key Country Dynamics
  - 7.4.7.3. Regulatory Framework
  - 7.4.7.4. Reimbursement Scenario
  - 7.4.7.5. Competitive Scenario
7.5. Latin America
- 7.5.1. Latin America Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.5.2.2. Key Country Dynamics
  - 7.5.2.3. Regulatory Framework
  - 7.5.2.4. Reimbursement Scenario
  - 7.5.2.5. Competitive Scenario
- 7.5.3. Argentina
  - 7.5.3.1. Argentina Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.5.3.2. Key Country Dynamics
  - 7.5.3.3. Regulatory Framework
  - 7.5.3.4. Reimbursement Scenario
  - 7.5.3.5. Competitive Scenario
7.6. MEA
- 7.6.1. MEA Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
- 7.6.2. South Africa
  - 7.6.2.1. South Africa Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.6.2.2. Key Country Dynamics
  - 7.6.2.3. Regulatory Framework
  - 7.6.2.4. Reimbursement Scenario
  - 7.6.2.5. Competitive Scenario
- 7.6.3. Saudi Arabia
  - 7.6.3.1. Saudi Arabia Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.6.3.2. Key Country Dynamics
  - 7.6.3.3. Regulatory Framework
  - 7.6.3.4. Reimbursement Scenario
  - 7.6.3.5. Competitive Scenario
- 7.6.4. UAE
  - 7.6.4.1. UAE Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.6.4.2. Key Country Dynamics
  - 7.6.4.3. Regulatory Framework
  - 7.6.4.4. Reimbursement Scenario
  - 7.6.4.5. Competitive Scenario
- 7.6.5. Kuwait
  - 7.6.5.1. Kuwait Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.6.5.2. Key Country Dynamics
  - 7.6.5.3. Regulatory Framework
  - 7.6.5.4. Reimbursement Scenario
  - 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

8.1. Company Categorization
8.2. Strategy Mapping
- 8.2.1. New Type Launch
- 8.2.2. Partnerships
- 8.2.3. Acquisition
- 8.2.4. Collaboration
- 8.2.5. Funding
8.3. Key Company Market Share Analysis, 2024
8.4. Company Heat Map Analysis
8.5. Company Profiles
- 8.5.1. Abbott
  - 8.5.1.1. Company Overview
  - 8.5.1.2. Financial Performance
  - 8.5.1.3. Type Benchmarking
  - 8.5.1.4. Strategic Initiatives
- 8.5.2. Bayer AG
  - 8.5.2.1. Company Overview
  - 8.5.2.2. Financial Performance
  - 8.5.2.3. Type Benchmarking
  - 8.5.2.4. Strategic Initiatives
- 8.5.3. BD
  - 8.5.3.1. Company Overview
  - 8.5.3.2. Financial Performance
  - 8.5.3.3. Type Benchmarking
  - 8.5.3.4. Strategic Initiatives
- 8.5.4. Cepheid
  - 8.5.4.1. Company Overview
  - 8.5.4.2. Financial Performance
  - 8.5.4.3. Type Benchmarking
  - 8.5.4.4. Strategic Initiatives
- 8.5.5. Agilent Technologies, Inc.
  - 8.5.5.1. Company Overview
  - 8.5.5.2. Financial Performance
  - 8.5.5.3. Type Benchmarking
  - 8.5.5.4. Strategic Initiatives
- 8.5.6. Danaher
  - 8.5.6.1. Company Overview
  - 8.5.6.2. Financial Performance
  - 8.5.6.3. Type Benchmarking
  - 8.5.6.4. Strategic Initiatives
- 8.5.7. Hologic, Inc.
  - 8.5.7.1. Company Overview
  - 8.5.7.2. Financial Performance
  - 8.5.7.3. Type Benchmarking
  - 8.5.7.4. Strategic Initiatives
- 8.5.8. Qiagen
  - 8.5.8.1. Company Overview
  - 8.5.8.2. Financial Performance
  - 8.5.8.3. Type Benchmarking
  - 8.5.8.4. Strategic Initiatives
- 8.5.9. F. Hoffmann-La Roche Ltd.
  - 8.5.9.1. Company Overview
  - 8.5.9.2. Financial Performance
  - 8.5.9.3. Type Benchmarking
  - 8.5.9.4. Strategic Initiatives
- 8.5.10. Siemens
  - 8.5.10.1. Company Overview
  - 8.5.10.2. Financial Performance
  - 8.5.10.3. Type Benchmarking
  - 8.5.10.4. Strategic Initiatives
- 8.5.11. Sysmex
  - 8.5.11.1. Company Overview
  - 8.5.11.2. Financial Performance
  - 8.5.11.3. Type Benchmarking
  - 8.5.11.4. Strategic Initiatives

한글목차

목차

제1장 종양 기반 분자진단 시장 : 조사 방법과 범위

제2장 종양 기반 분자진단 시장 : 주요 요약

제3장 종양 기반 분자진단 시장 변수, 동향 및 범위

제4장 종양 기반 분자진단 시장 : 유형별, 추정 및 동향 분석

제5장 종양 기반 분자진단 시장 : 제품별, 추정 및 동향 분석

제6장 종양 기반 분자진단 시장 : 기술별, 추정 및 동향 분석

제7장 종양 기반 분자진단 시장 : 지역 비즈니스 분석

제8장 경쟁 구도